MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

Phase 2

MYLAN (VTRS)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

VTRSPhase 2$17.9B

MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) Phase 2 Est. Readout

MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)• Contraception60

Nov 2026~Confirmed

CT.gov

00%

Competitive Landscape

4 competitors in Contraception

BAYRYLong-acting reversible contraceptives

BAYRYcontraceptives

BAYRYContraceptives business

JNJnorelgestromin + ethinyl estradiol

Phase 3

View Full Landscape

Drug Information

Target Indication

Contraception

Clinical Trial

NCT07365904

Last updated: 1/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VTRS

MYLAN

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MYL-1601D ProductPhase 3

Diabetes Mellitus, Type 1

venlafaxine ER 75 mg/day (fixed dose)Phase 3

Major Depressive Disorder

LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATIONPhase 3

Glaucoma, Primary Open Angle (POAG)

RevefenacinPhase 3

Chronic Obstructive Pulmonary Disease, COPD

Amlodipine/atorvastatin single pillPhase 3

Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts